Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31105686 | 0.81 | CRBN (0.64) | CRBNDDB1 | |
| SCHEMBL30643657 | 0.81 | DDB1 (0.68) | CRBNDDB1SIGMAR1 | |
| SCHEMBL25570863 | 0.81 | DDB1 (0.68) | CRBNDDB1SIGMAR1 | |
| SCHEMBL31731817 | 0.81 | CRBN (0.64) | CRBNDDB1 | |
| SCHEMBL26266554 | 0.81 | CRBN (0.64) | CRBNDDB1 | |
| SCHEMBL31731890 | 0.81 | CRBN (0.64) | CRBNDDB1 | |
| Hydrochloric Acid SCHEMBL25217943 | 0.80 | DDB1 (0.67) | CRBNDDB1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL30429707 | 0.80 | DDB1 (0.67) | CRBNDDB1SIGMAR1 | |
| SCHEMBL31091741 | 0.78 | DDB1 (0.59) | CRBNDDB1SIGMAR1 | |
| SCHEMBL31447691 | 0.77 | DDB1 (0.53) | CRBNDDB1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |